HIF1A and neoplasm: However, it also has been reported that tocilizumab could inhibit tumor growth through impairing tumor-related neovascularization and main proangiogenic factor VEGF-A and its transactivator HIF-1α in humanized breast orthotopic tumor xenografts [51].